Immunotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized clinical trials.

Ther Adv Med Oncol · 2026 · PMC12883717 · PMID 41669379

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

LRFS showed a nonsignificant trend toward benefit (HR 0.67, 95% CI: 0.41–1.11; I 2 = 43.6%), though a clear advantage was evident in cisplatin-based regimens (HR 0.53, 95% CI: 0.34–0.82).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.